Relevant achievement analysis based on the China Scientific & Technological Achievements Database (CSTAD)
Data source: CSTAD is a database of achievements using new technology, which has become the most authoritative technical achievement database in China because of its level of accuracy and detail. In addition to new achievements and technology transfer, this database also provides technical advice and information sources for use in technical reform, product development and process innovation. There are 815,971 items in various disciplines of natural science, which include national-level scientific and technological achievements, with a scope of new technologies, products, processes, materials, and designs. ClinicalTrials.gov data analysis Data source: ClinicalTrials.gov is a website that provides patients, family members, healthcare professionals, and members of the public easy access to information on clinical trials sponsored by the National Institutes of Health, other federal agencies, and the pharmaceutical industry, for a wide range of diseases and conditions. The US National Institutes of Health (NIH) developed the site through its National Library of Medicine in collaboration with the Food and Drug Administration and all NIH institutes. The site was made available to the public in February 2000 and currently contains 173,477 clinical studies conducted in 187 countries. Time span: 2000-′2014. Search terms: (sanqi or "panax notoginseng") and (stroke or "cerebral infarction" or "brain ischemia"). Inclusion criteria: (1) study participants are not yet being recruited; (2) participants are currently being recruited; (3) participants are being (or will be) selected from a predetermined population; (4) study is ongoing, but participants are not currently being recruited or enrolled; (5) the study has concluded normally and participants are no longer being examined or treated; (6) recruiting or enrolling of participants has halted prematurely but may resume; (7) recruiting or enrolling of participants has halted prematurely and will not resume and participants are no longer being examined or treated; (8) study halted prematurely, prior to enrollment of first participant.
Meta-analysis of the Cochrane Library
The Cochrane Library (http://www.thecochranelibrary. com/) is a collection of databases in medicine and other healthcare specialties provided by the Cochrane Collaboration from 1992. Its aim is to make the results of well-conducted controlled trials readily available and is a key resource in evidence-based medicine. To date, 8,616 systemic reviews have been checked by the Cochrane Collaboration. Time span: 1993-2014. Search terms: (sanqi or "panax notoginseng") and (stroke or "cerebral infarction" or "brain ischemia").
Results

Web of Science
The Web of Science contains 783 papers addressing radix notoginseng as a treatment for ischemic brain injury, focusing mainly on pharmaceutical and chemical analysis. Only 26 out of the 783 papers are associated with the neuroprotective role of radix notoginseng; these have been cited 166 times in 141 articles (average times cited, 6.38; h-index, 9). These papers are mainly from China (22/26), as well as Korea and Japan. Table 1 shows the most cited original articles addressing the use of radix notoginseng in the treatment of ischemic brain injury on the Web of Science from 2005 to 2014.
The top cited paper ) is from the National Chung Hsing University, Graduate Institute of Biotechnology, Taiwan, China. The main research focus of the laboratory of Jason T. C. Tzen, the corresponding author, is the active ingredients of radix notoginseng and the molecular mechanisms underlying its effects in the human body.
The second and fifth most popular papers were both from the Department of Pharmacology, Sun Yat-sen University, China. The relevant studies were funded by the National Natural Science Foundation of China (No. 30730105), National Basic Research Program of China (Program 973; No. 2009CB521903) , and Science Foundation of Guangzhou in China. The corresponding author, Yongyuan Guan, works in a laboratory that studies the effects of radix notoginseng on ion channels and neuroprotection. In these two papers addressing the purified ingredients of Panax notoginseng saponins, the authors propose that ginsenoside Rd can significantly inhibit calcium overload following middle cere- bral artery occlusion, prevent Ca 2+ influx in vascular smooth muscle, dilate the cerebral blood vessels, and improve cerebral circulation; moreover, radix notoginseng can be used against glutamate-induced apoptosis in rat cortical neurons. The third most popular paper comes from Guangdong General Hospital, Guangdong Academy of Medical Science, China. In this paper, Panax notoginseng saponins are shown to protect local ischemia-induced apoptosis in vitro and in vivo by activating the PI3K/Akt signaling pathway .
The fourth most popular paper came from Dongguk University, Korea (Son et al., 2009 ). Park and co-workers found that radix notoginseng eased inflammation in the infarcted region and reduced the infarct volume, providing sound evidence that Panax notoginseng saponins are effective against inflammation.
The above papers were mainly published in the following journals listed in the SCI (Figure 1) . Main journal output A total of 1 320 articles concerning the use of radix notoginseng for ischemic brain injury were included in CNKI from 2005 to 2014, published mainly in the journals shown in Figure 2 and discussed below. In the past 10 years, the Chinese Traditional Patent Medicine has published the most articles (38), among which the three most-cited are "Effect of Panax notoginseng on cerebral ischemia-reperfusion injury in rats" (Jiang et al., 1995; 63 citations) , "Effect of Panax ginseng, Panax pseudoginseng, Acanthopanax and Schisandra on protein biosynthesis in mouse brain" (Ye et al., 1993; 30 citations) , and "Effect of Panax notoginseng saponins on the expression of BNDF in rats with cerebral ischemia reperfusion" 23 citations) . The top three most downloaded articles are "Quantitative determination of notoginsenoside R1 and ginsenoside Rg1, Rb1 contents in Xinnao Guantong Guttate Pill by HPLC gradient elution method" (Liu et al., 2007; 240 downloads) , "Effect of Sanqi Tongshu Capsule on Syp and PSD-95 expression of different periods of cerebral infarction" (Cui et al., 2008; 243 downloads) , and "Advanced development of new preparation and component of Salvia and Panax notoginseng" 63 downloads (Figure 2) .
Research hotspots
High-frequency keywords in the databases reflect the direction of research and commonly covered subjects, as well as the hot topics and research questions across different time periods. The 10 most popular keywords listed in articles related to the use of radix notoginseng for ischemic brain injury in the CNKI and Wanfang databases over the past 10 years are listed in Table 2 .
Research fronts
The most relevant keywords relating to the treatment of ischemic brain injury with radix notoginseng occur in the Wanfang database, reflecting the research direction of cross-sectional studies in this field. The 10 most popular keywords searched by the researchers are: risk factors; hemorrheology; extraction process; ginseng; high performance liquid chromatography; thin layer chromatography; ginsenosides; Salvia mittiorrhiza; chemical composition; content determination. Based on these words, we can conclude that the researchers were more interested on the main active ingredients of radix notoginseng and the quality of its preparation, as well as the mechanisms underlying its effects in the treatment of ischemic brain injury.
Most-cited articles and authors
The most-cited articles in CNKI between 2005 and 2014, which address radix notoginseng in the treatment of ischemic brain injury, are listed in Table 3 .
Changqing Deng (Li et al., 2006) is the corresponding author with the most citations and comes from Hunan University of Chinese Medicine in China. He is engaged in basic research on Buyang Huanwu Tang and Panax notoginseng saponins in the treatment of cerebral ischemia-reperfusion. His 34 articles are included in the Wanfang database and cited 256 times, with an h-index of 9.
Changqing Deng is a prolific author, publishing every year for the past decade. In 2012, he published eight articles (Figure 3) . This author collaborates with the authors shown in Figure 4 , who study radix notoginseng and neurological diseases, and has been repeatedly funded by the National Natural Science Foundation of China and the Chinese Academy of Sciences.
Most productive institutions
Based on data from the CNKI database (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) , the most productive institutions in this 10-year period are the Beijing University of Chinese Medicine with 40 articles and Kunming Medical University with 20 articles (Table 4) . 
Main funding projects
Technological achievements
We retrieved 92 rewarded or planned achievements concerning radix notoginseng in the treatment of ischemic brain injury at provincial-, municipal-level, and ministerial-levels from CSTAD between 2009 and 2014. Among these 92 achievements, 70 are related to medicine and health, and 22 to industrial technology. In 2008, the most funded project in China was supported by 17 funds, but this number shows a declining trend since 2008 (Figure 5 ).
ClinicalTrials.gov database
To date, only two clinical trials concerning radix notoginseng for ischemic brain injury have been registered in ClinicalTrials.gov, both of which come from China ( Table 5) .
Cochrane Library
Only one study, "Sanchi for acute ischaemic stroke", classifiable as a randomized or quasi-randomized controlled clinical trial of Panax preparations for the treatment of acute ischemic stroke, was retrieved in the Cochrane Library (http://www.thecochranelibrary.com/). The study was reported by Chen et al. (2008) The authors screened a total of eight randomized controlled trials. A significant difference was found between radix notoginseng and placebo or no treatment in the therapeutic efficacy against acute ischemic stroke within 30 days of treatment. There were 660 participants enrolled in the studies reported in these eight articles. Seven of the articles show poor quality, six of which have a follow-up period of less than 1 month. Only two of the eight articles show that if treatment continues for 28 days, the use of radix notoginseng can significantly reduce the mortality and disability of patients after acute ischemic stroke. One of these two articles reports a higher Barthel index in the patients undergoing radix notoginseng treatment. Comprehensive analysis of seven studies shows that radix notoginseng can significantly improve neurological deficits. The overall mortality rate is less than 1%, indicating that the participants mostly appear to have mild stroke and fewer adverse reactions. However, there is little information about the quality of life or stroke recurrence. Based on the available evidence, the authors conclude that radix notoginseng may be effective for the treatment of acute ischemic stroke. However, the low number and poor quality of the included studies results in considerable bias, so we cannot be certain of the efficacy and safety of radix notoginseng in the treatment of acute ischemic stroke.
Discussion
The majority of the 1 320 articles from CNKI focus on experimental research to explore the mechanism of radix notoginseng in the treatment of ischemic brain injury, while the 1 134 articles from Wanfang mainly address its clinical use. Researchers are also concerned with the main active ingredients of Panax notoginseng, the quality of Panax notoginseng preparations, and relevant clinical results.
Animal studies have found that Panax notoginseng saponins can significantly improve behavior symptoms, relieve brain edema, and reduce infarct size in rat models of cerebral ischemia. Cytological, morphological and lipid oxidation studies have shown that Panax notoginseng saponins can reduce serum malondialdehyde content and increase superoxide dismutase activity in the brain, suggesting that they protect against nerve cell damage from energy metabolism disorders, and also function as cerebrovascular regulators.
Literature on the mechanism of Panax notoginseng saponins has mainly concentrated on the following subjects: (1) the role of Panax notoginseng saponins in mouse global cerebral ischemia and rat focal cerebral ischemia; (2) their protective role in primary rat cerebral cortical neurons; (3) their effect on brain tissue blood supply; (4) their effect on energy metabolism; (5) their effect on intracellular free calcium concentration; (6) their effect on the calcium intake capacity of synaptosomes; (7) their effect on the release of excitatory amino acids and specific binding to the receptor; (8) their inhibitory effect on the oxidation of rat liver and brain homogenates and lipid peroxidation induced by the Fe 2+ /ascorbic acid system; (9) their effect on platelet function.
Only two trials on the use of radix notoginseng in the treatment of ischemic brain injury have been registered on ClinicalTrials.gov. Both are in the recruitment period and expected to recruit 120 cases, with no results announced yet.
Conclusion
In China, Panax notoginseng has been used for a long time and is considered to be an effective treatment for ischemic stroke. Relevant articles about its clinical use, however, are lacking in quality. There remains a need for more rigorous large-scale randomized controlled clinical trials with extended follow-up periods to determine the clinical efficacy of Panax notoginseng in improving the quality of life and reducing stroke recurrence after acute ischemic stroke.
